Methods of Cancer Diagnosis, Therapy and Prognosis

"Once more Professor Hayat has to be congratulated for bringing together 56 leading scientists representing 16 countries in the field of breast cancer, which has made it possible to publish such an excellent book. It represents a valuable addition to the available literature on breast cancer treatment since it covers all aspects of breast cancer, including diagnosis, treatments, and prognosis. Thereby, not only efficacy of various anticancer drugs and their side-effects are pointed out, but also the necessity of age-dependent breast cancer strategies is highlighted. Therefore, I conclude that this book is a true benefit to all clinicians, surgeons, and oncologists working in the field of breast cancer." Professor Dr. Thomas Dittmer Institute of Immunology Witten/Herdecke University Witten, Germany "This first volume of the Handbook on Methods of Cancer Diagnosis, Therapy, and Prognosis, concerns problems related to diagnosis, treatment, monitoring of therapy, and prognosis in breast cancer. This is an impressive monograph containing data range on novel techniques (e.g., PET examination of sentinel lymph nodes) used in early diagnosis, prognosis (Molecular studies on circulating neoplastic cells), and treatment (surgery, chemo-radio-and hormontherapy) of various histological types of breast cancer. This monograph resulting from cooperative efforts of 56 authors from 16 countries (specialists in this field) cannot be matched by any publication of this type. The oncologists, pathologists, and scientists engaged in problems of breast cancer should have this extremely valuable Handbook at hand." Professor Piotr Dziegiel Department of Histology and Embryology Medical University of Wroclaw, Poland "It has been a great pleasure to review the forthcoming book, Methods of Cancer Diagnosis, Therapy, and Prognosis: Volume 1, edited by Professor M.A. Hayat. Dr. Hayat is a Distinguished Professor in the Department of Biological Sciences, Kean University, Union, New Jersey. After seeing the chapters listed in his book, I am very impressed by the thoroughness of the topics in the proposed book. As an editor, Dr. Hayat has assembled a group of well known researchers and clinicians from many parts of the world to write the state-of-the art chapters on breast cancer, including but not limited to the chapters, on computer-assisted diagnosis, familial breast cancer, serum markers in diagnosis, circulating cancer cells before and after treatments, epigenetic markers, metastasis and its detection, validation of biomarkers, immunohistochemistry, invasive cancer and treatments. He has summarized the problems associated with the complexities of research publications which are not easy reading even for many scientists and clinicians. The subject matter is, undoubtedly, complex and formidable for many breast cancer patients. The current consolidated information on breast cancer research is not readily available. The numbers of cancer cases are projected to increase significantly by 2030, especially in low and middle income countries. Even in the advanced countries, there is a population of low and middle income people who do not have access to appropriate diagnosis and treatment. These people suffer from the same problems as those belonging to the low and middle income countries. Dr. Hayat has provided data in his preface showing that some cancers can be reduced by changes in lifestyle and education. His assessment is very timely. With best wishes and regards to Dr. Hayat." Akhouri A. Sinha, Ph.D. Professor of Genetics, Cell Biology and Development, The University of Minnesota and Research Scientist at the Veterans Affairs Medical Center, Minneapolis, Minnesota. "Professor Hayat has done it again! He has edited (METHODS OF CANCER DIAGNOSIS, THERAPY, AND PROGNOSIS, to be published by Springer) a comprehensive treatise on diagnosis, therapy, recurrence, resistance along with risk benefit ratio in cancers with special emphasis on breast cancer. Scientists and clinicians from the world over have contributed the latest advances in their respective areas of expertise. The reader is provided with a whole field view of the state of the art in breast cancer management. This treatise will serve as a must read for oncologists, scientist researchers and students of cancer biology. I look forward to the next series dealing with epidemiology, genetic predisposition and the role of the tumor microenvironment in cancer biology." Debabrata Banerjee Ph.D Associate Professor Medicine and Pharmacology Cancer Institute of New Jersey, New Brunswick

• General Methods and Overviews.- Metabolic Transformations of Malignant Cells: An Overview.- Detection of Recurrent Cancer by Radiological Imaging.- Tumor Gene Therapy: Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy.- Assessment of Gene Transfer: Magnetic Resonance Imaging and Nuclear Medicine Techniques.- Role of TP53 Mutations in Cancer (An Overview).- Personalized Medicine for Cancer.- Radiation Doses to Patients Using Computed Radiography, Direct Digital Radiography, and Screen-Film Radiography.- Cancer Vaccines and Immune Monitoring (An Overview).- New Insights into the Role of Infection,Immunity and Apoptosis in the Genesis of the Cancer Stem Cell.- Successful Cancer Treatment: Eradication of Cancer Stem Cells.- Overexposure of Patients to Ionizing Radiation: An Overview.- Lung Cancer.- Lung Carcinoma.- Extra-Pulmonary Small Cell Cancer: Diagnosis, Treatment, and Prognosis.- Magnetic Resonance Imaging of the Lung: Automated Segmentation Methods.- Peripheral Lung Lesions: Diagnosis Using Transcutaneous Contrast-Enhanced Sonography.- Small Pulmonary Nodules: Detection Using Multidetector-Row Computed Tomography.- Secondary Primary Cancer Following Chemoradiation for Non-Small-Cell Lung Cancer.- Advanced Non-Small Cell Lung Cancer: Second-Line Treatment with Docetaxel.- Non-Small Cell Lung Cancer with Brain Metastases: Platinum-Based Chemotherapy.- Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib.- Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib.- Prognostic Significance of [18F]-Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Pathological Stage I Lung Adenocarcinoma.- Non-Small Cell Lung Cancer: Prognosis Using the TNM Staging System.- Differentiation Between Malignant andBenign Pleural Effusions: Methylation Specific Polymerase Chain Reaction Analysis.- Pathological Distinction of Pulmonary Large Cell Neuroendocrine Carcinoma from Small-Cell Lung Carcinoma Using Immunohistochemistry.- Differentiation Between Pleuropulmonary Desmoid Tumors and Solitary Fibrous Tumors: Role of Histology and Immunohistochemistry.- Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation.- Prostate Cancer.- Prostate Carcinoma.- The Role of Intermediary Metabolism and Molecular Genetics in Prostate Cancer.- Array-Based Comparative Genomic Hybridization in Prostate Cancer: Research and Clinical Applications.- Prostate Cancer: Role of Vav3 Overexpression in Development and Progression.- Prostate Cancer: Detection and Monitoring Using Mitochondrial Mutations as a Biomarker.- Prognostic Markers in Prostatic Carcinoma.- Prostate Cancer: Detection of Free Tumor-Specific DNA in Blood and Bone Marrow.- Prostate Carcinoma: Evaluation Using Transrectal Sonography.- Prostate Cancer: 16?-[18F] Fluoro-5?-Dihydrotesterone (FDHT) Whole-Body Positron Emission Tomography.- Effects of Standard Treatments on the Immune Response to Prostate Cancer.- Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer.- Locally Advanced Prostate Cancer Biochemical Recurrence after Radiotherapy: Use of Cyclic Androgen Withdrawal Therapy.